To investigate the effect of FAK inhibitors in breast cancer cells with FAK-copy-gain, the relative level changes of activated FAK or phosphorylated FAK (pFAK) at Y397 were monitored after F14 treatment. This evidence concerns the gene PTK2 and breast carcinoma.